conceptual period 

Recipient: Free University of Berlin
Funding: GO-Bio initial feasibility phase 3 (01/10/2022 to 30/09/2023, EUR 119,826.00)

As life expectancy increases, so too does the probability of developing cancer. Despite medical progress and global efforts, the cure rate for important tumor important tumor indications has stagnated for decades. One reason for this is the escape of tumor cells during therapy into a senescent state - a kind of state - a kind of Sleeping Beauty sleep - during which they lose their

ability to divide. Nevertheless, it is possible that the tumor cells reawaken and become particularly aggressive. The project Senolytika therefore starts during the senescent state. Using a novel active substance, a senolytic, the "dormant" cells are selectively eliminated. This is intended to protect cancer patients from tumor recurrence. An important advantage of the procedure is that the novel active ingredient of the Senolytika project specifically targets characteristic features of the

metabolism of senescent cells without attacking specific cellular targets. This unique approach makes it possible to eliminate senescent cells without damaging healthy cells. Within the "GO-Bio initial" conceptual phase the commercial exploitation potential of the novel senolytic potential of the novel senolytic and to create the conditions for the commercially successful implementation.

feasibility stage

Recipient: Free University of Berlin
Funding: GO-Bio initial feasibility phase 3 (01/10/2023 to 30/09/2025, EUR 1,016,767.61)

As life expectancy increases, so does the likelihood of developing cancer. However, despite medical advances and global efforts the cure rate for important tumour indications has stagnated for decades. One reason for this entails the escape of the tumour cells during therapy into the senescent state, a kind of deep sleep, where they lose their ability to divide and cancer drugs can no longer kill these cells. Nevertheless, it is possible that they reawaken from senescence after therapy and then return to particularly aggressive tumour growth. This is exactly where this project comes in. By means of a senolytic, the active ingredient developed in this project, the senescent cells are selectively eliminated in order to protect treated cancer patients from tumour relapse. The active ingredient specifically exploits characteristic features of the metabolism of these cells. Such an approach makes it possible to selectively and broadly eliminate senescent cells without damaging healthy cells. The aim of this project is to advance the preclinical development, to test the feasibility of the idea in suitable therapy models and thus to prepare the senolytic for utilisation. The team constellation for the spin-off is determined and intellectual property rights are registered. The feasibility phase prepares the project in the best possible way for compatibility with established funding programmes.